Seaport Therapeutics(SPTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPTX Seaport Therapeutics

未开盘 08-04 16:00:00 EDT

21.43

+0.78

+3.78%

盘后21.43

+0.000.00%

19:00 EDT

最高21.86	最低20.34	成交量8.99万
今开20.34	昨收20.65	日振幅7.34%
总市值11.36亿	流通市值6.06亿	总股本5,303万
成交额191.87万	换手率0.32%	流通股本2,829万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPTX","market":"US","secType":"STK","nameCN":"Seaport Therapeutics","latestPrice":21.43,"timestamp":1785873600000,"preClose":20.65,"halted":0,"volume":89901,"hourTrading":{"tag":"盘后","latestPrice":21.43,"preClose":21.43,"latestTime":"19:00 EDT","volume":441,"amount":9451.06,"timestamp":1785884402667,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03777239709443105,"floatShares":28294359,"shares":53027817,"eps":-1.628,"marketStatus":"未开盘","change":0.78,"latestTime":"08-04 16:00:00 EDT","open":20.34,"high":21.855,"low":20.34,"amount":1918696,"amplitude":0.073366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.628,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785916800000},"marketStatusCode":0,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":20.65,"postHourTrading":{"tag":"盘后","latestPrice":21.43,"preClose":21.43,"latestTime":"19:00 EDT","volume":441,"amount":9451.06,"timestamp":1785884402667,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.881208},"requestUrl":"/m/hq/s/SPTX/tweets","defaultTab":"tweets","newsList":[{"id":"1142309956","title":"Seaport Therapeutics发布2026年第二季度财务业绩，并强调近期企业与临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1142309956","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142309956?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:01","pubTimestamp":1785754872,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics近日公布了其2026年第二季度的财务报告，同时着重强调了公司在企业运营及临床开发方面的最新进展。这份公告不仅涵盖了关键的财务数据，还详细披露了公司近期取得的里程碑式成就，为投资者提供了全面的业务更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123404378","title":"Seaport Therapeutics 获 H.C. Wainwright 首次覆盖，给予买入评级及50美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1123404378","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123404378?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:11","pubTimestamp":1784110277,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics 获得了 H.C. Wainwright 的首次关注，该机构对其启动了覆盖研究，并给出了积极的“买入”评级。分析师团队为这家生物制药公司设定了50美元的目标股价，预示着对其未来增长潜力的坚定看好。此举标志着资本市场对该公司研发管线与商业前景的进一步认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136030739","title":"Seaport Therapeutics公布2026年第一季度财务业绩并强调近期公司及临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1136030739","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136030739?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:05","pubTimestamp":1780916727,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics公布了其2026年第一季度的财务业绩，并重点介绍了近期的公司运营与临床研发进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159152611","title":"Seaport Therapeutics - 七日Glyphago给药实现治疗性阿戈美拉汀暴露，无肝酶升高","url":"https://stock-news.laohu8.com/highlight/detail?id=1159152611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159152611?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:04","pubTimestamp":1780916669,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。\n研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133710650","title":"Seaport Therapeutics公布Glyphago™在健康受试者中1期概念验证试验的多次递增剂量积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1133710650","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133710650?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:02","pubTimestamp":1780916559,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics公布了其候选药物Glyphago™在健康受试者中进行的1期概念验证试验的多次递增剂量数据，结果积极。\n该试验旨在评估Glyphago™在多次递增剂量下的安全性、耐受性及药代动力学特征。数据显示，在试验的剂量范围内，药物表现出良好的耐受性，未出现严重不良事件。同时，药代动力学参数符合预期，支持进一步的临床开发。\n这些积极的初步数据为Glyphago™后续在目标患者群体中的研究奠定了基础。公司计划基于这些结果推进该项目的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189804894","title":"Seaport Therapeutics - Glyphago重复给药显示良好安全性且无肝脏相关不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1189804894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189804894?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:02","pubTimestamp":1780916551,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其Glyphago药物的重复给药研究显示出良好的安全性特征，且未观察到与肝脏相关的不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954794","title":"Seaport Therapeutics将出席两大投资者会议，聚焦神经精神药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954794","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640954794?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:09","pubTimestamp":1780319340,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics是一家专注于开发新型神经精神疾病疗法的临床阶段生物制药公司，近日宣布其管理团队将参与两场即将举行的投资者会议。　　根据公司发布的消息，Seaport将出席高盛第47届年度全球医疗保健会议，炉边谈话定于2026年6月10日上午8点举行。　　Seaport Therapeutics总部位于马萨诸塞州波士顿，于2024年成立，2026年5月1日在纳斯达克完成IPO上市，股票代码为SPTX。此次参与两大投资者会议，Seaport将向投资界分享其在神经精神药物研发领域的最新进展与战略规划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5038397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","SPTX","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630375655","title":"神经精神治疗药物开发商Seaport(SPTX.US)IPO定价16-18美元/股 拟筹资2.01亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630375655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630375655?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:08","pubTimestamp":1777363680,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发神经精神适应症疗法的生物科技公司Seaport Therapeutics周一公布了其首次公开募股条款。该公司计划以每股16-18美元的价格发行1180万股股票，筹资2.01亿美元。该公司预计于本周确定IPO发行价。据悉，Seaport Therapeutics是一家临床阶段的生物科技公司，致力于开发治疗神经精神疾病的口服疗法。此外，公司还有针对抑郁症及相关中枢神经系统疾病的临床前候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UDN","IPOS","SPTX","UUP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.seaporttx.com","stockEarnings":[{"period":"1week","weight":0.0769},{"period":"1month","weight":0.0418},{"period":"3month","weight":0.3394},{"period":"6month","weight":0.1906},{"period":"ytd","weight":0.1906}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Seaport Therapeutics, Inc.于2024年4月1日根据特拉华州法律成立。该公司是一家临床阶段治疗公司，专注于抑郁症、焦虑症和其他神经精神疾病，应用其专有的Glyph平台开发新型口服疗法。Glyph是一种淋巴靶向前药技术，旨在绕过首过代谢，增强口服生物利用度，并减少副作用。","exchange":"NASDAQ","name":"Seaport Therapeutics","nameEN":"Seaport Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Seaport Therapeutics(SPTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Seaport Therapeutics(SPTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Seaport Therapeutics,SPTX,Seaport Therapeutics股票,Seaport Therapeutics股票老虎,Seaport Therapeutics股票老虎国际,Seaport Therapeutics行情,Seaport Therapeutics股票行情,Seaport Therapeutics股价,Seaport Therapeutics股市,Seaport Therapeutics股票价格,Seaport Therapeutics股票交易,Seaport Therapeutics股票购买,Seaport Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Seaport Therapeutics(SPTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Seaport Therapeutics(SPTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}